These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Goto Y; Niidome T; Hongo H; Akaike A; Kihara T; Sugimoto H Eur J Pharmacol; 2008 Mar; 583(1):84-91. PubMed ID: 18282567 [TBL] [Abstract][Full Text] [Related]
6. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Pákáski M; Kálmán J Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Nordberg A Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751 [TBL] [Abstract][Full Text] [Related]
8. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Sparks DL; Martin TA; Gross DR; Hunsaker JC Microsc Res Tech; 2000 Aug; 50(4):287-90. PubMed ID: 10936882 [TBL] [Abstract][Full Text] [Related]
9. [Neurotransmitters in Alzheimer's disease]. Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771 [TBL] [Abstract][Full Text] [Related]
10. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Davidson M; Stern RG Psychiatr Clin North Am; 1991 Jun; 14(2):461-82. PubMed ID: 2062728 [TBL] [Abstract][Full Text] [Related]
11. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Pan X; Gong N; Zhao J; Yu Z; Gu F; Chen J; Sun X; Zhao L; Yu M; Xu Z; Dong W; Qin Y; Fei G; Zhong C; Xu TL Brain; 2010 May; 133(Pt 5):1342-51. PubMed ID: 20385653 [TBL] [Abstract][Full Text] [Related]
12. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468 [TBL] [Abstract][Full Text] [Related]
13. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Liu L; Ikonen S; Heikkinen T; Tapiola T; van Groen T; Tanila H Exp Neurol; 2002 Feb; 173(2):196-204. PubMed ID: 11822883 [TBL] [Abstract][Full Text] [Related]
14. Decorated plaques in Alzheimer's disease. Tabira T Ann Neurol; 2009 Jan; 65(1):4-6. PubMed ID: 19194874 [No Abstract] [Full Text] [Related]
15. Alzheimer's disease therapeutics: new approaches to an ageing problem. Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347 [TBL] [Abstract][Full Text] [Related]
16. Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease. Montalto MC; Farrar G; Hehir CT Ann N Y Acad Sci; 2007 Feb; 1097():239-58. PubMed ID: 17413026 [TBL] [Abstract][Full Text] [Related]
17. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease. Sipos E; Kurunczi A; Kasza A; Horváth J; Felszeghy K; Laroche S; Toldi J; Párducz A; Penke B; Penke Z Neuroscience; 2007 Jun; 147(1):28-36. PubMed ID: 17499931 [TBL] [Abstract][Full Text] [Related]
18. Intracellular amyloid-beta in Alzheimer's disease. LaFerla FM; Green KN; Oddo S Nat Rev Neurosci; 2007 Jul; 8(7):499-509. PubMed ID: 17551515 [TBL] [Abstract][Full Text] [Related]
19. [Research progress on Alzheimer's disease: pathogenesis and medical therapy]. Sheng SL Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):101-3. PubMed ID: 15171541 [TBL] [Abstract][Full Text] [Related]
20. The role of nicotinic acetylcholine receptors in Alzheimer's disease. Oddo S; LaFerla FM J Physiol Paris; 2006; 99(2-3):172-9. PubMed ID: 16448808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]